Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 6/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 4/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12873177 | 0.89 | CALCRL (0.37) | ERBB2BACE1BACE2CALCRLPTPN1 | |
| SCHEMBL2742710 | 0.89 | CALCRL (0.37) | ERBB2BACE1BACE2CALCRLPTPN1 | |
| SCHEMBL21766768 | 0.87 | PSMB5 (0.36) | ERBB2PSMB5RENKEAP1CALCRL | |
| SCHEMBL29961965 | 0.86 | CALCRL (0.37) | ERBB2BACE1BACE2CALCRL | |
| SCHEMBL30009160 | 0.85 | CALCRL (0.48) | BACE1BACE2CALCRL | |
| SCHEMBL30788325 | 0.80 | BACE1 (0.38) | CTSDBACE1BACE2 | |
| SCHEMBL21766737 | 0.80 | MAGI3 (0.39) | BACE1BACE2KEAP1PTPN1 | |
| SCHEMBL30008256 | 0.79 | BACE1 (0.39) | CTSDBACE1BACE2 | |
| SCHEMBL30632044 | 0.79 | PTPN1 (0.39) | KEAP1PTPN1 | |
| SCHEMBL21766784 | 0.79 | ERAP2 (0.37) | ERBB2BACE1BACE2KEAP1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | ERBB2 2372/4885CTSD 918/4885BACE1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.